Seroatlas · Human Serome Atlas

CD300LD

CMRF35-like molecule 5

Also known as: CD300D, CLM5_HUMAN, CMRF35A4

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6UXZ3
Gene: CD300LD
Ensembl: ENSG00000204345
Chromosome: 17
Canonical length: 194 aa
Protein class: CD markers, Predicted membrane proteins

OverviewNCBI Gene

Predicted to enable transmembrane signaling receptor activity and virus receptor activity. Predicted to be involved in immune response-activating signaling pathway. Predicted to act upstream of or within regulation of interleukin-6 production and regulation of tumor necrosis factor production. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

194 residues, UniProt reviewed canonical sequence.

>Q6UXZ3|CD300LD
     1  MWLSPSLLLL ILPGYSIAAK ITGPTTVNGS EQGSLTVQCA YGSGWETYLK WRCQGADWNY
    61  CNILVKTNGS EQEVKKNRVS IRDNQKNHVF TVTMENLKRD DADSYWCGTE RPGIDLGVKV
   121  QVTINPGTQT AVSEWTTTTA SLAFTAAATQ KTSSPLTRSP LKSTHFLFLF LLELPLLLSM
   181  LGTVLWVNRP QRRS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CD300LD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.45
Highest tissue expression: 0.8 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 0.8 nTPM
appendix: 0.5 nTPM
skin: 0.4 nTPM
retina: 0.3 nTPM
salivary gland: 0.3 nTPM
small intestine: 0.3 nTPM

Single-cell type

monocytes: 3.6 nCPM
breast lactating cells: 2.6 nCPM
epicardial cells: 2.3 nCPM
neutrophils: 2.1 nCPM
salivary acinar cells: 1.3 nCPM
early spermatids: 0.7 nCPM

Immune cell

neutrophil: 5.1 nTPM
T-reg: 0.8 nTPM
basophil: 0.6 nTPM
intermediate monocyte: 0.4 nTPM
myeloid DC: 0.4 nTPM
NK-cell: 0.4 nTPM

Brain region

cerebellum: 4.3 nTPM
cerebral cortex: 3.9 nTPM
white matter: 3.7 nTPM
basal ganglia: 3.4 nTPM
hippocampal formation: 3.4 nTPM
thalamus: 3.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.57
gnomAD pLI: 0
gnomAD missense Z: 0.12
DepMap mean gene effect: 0.22
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CD300LD in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

FCER1G

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CD300LD as an antibody target. Whether an autoantibody or antibody against CD300LD could matter depends on whether native CD300LD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CD300LD is annotated at the cell surface, where native CD300LD is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CD300LD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...